A general overview of what recent studies say about GLP-1 agonists. The link carries the full piece, with no specific findings shared up front.
Recap by typeshit. Post by indicanews.com on X.
A brief Facebook post says a daily pill might help people who worry about putting weight back on once they come off Wegovy. It names no drug or study.
In 367 adults with type 2 diabetes, the top combo dose beat 14.8% on tirzepatide alone at 48 weeks. Lilly plans phase 3 by late 2026.
Alessandro Sette's lab will track T cell responses in people before and after starting GLP-1s, including to Parkinson's-linked proteins. He is enrolling himself too.
12:35
Dr. Eric Berg walks through the basics of peptides in a broad explainer. Treat any health claims as his own views.
An AI chatbot answer lays out single, dual and triple agonists, noting Lilly's retatrutide adds the glucagon receptor and is still investigational.
Nausea hit 20% of users vs 6% on placebo, with other gut effects near placebo levels. A GP tells Medical News Today phase 3 data is still needed.
Loading…